Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist

Fertility and Sterility

Volumn 93, Issue 5, 2010, Pages 1609-1614

  Ozcelik, Bulent ^a   Turkyilmaz, Cagdas ^a   Ozgun, Mahmut Tuncay ^a   Serin, Ibrahim Serdar ^a   Batukan, Cem ^a   Ozdamar, Saim ^a   Ozturk, Ahmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

chemotherapy; GnRH agonist; ovarian damage; rat

Indexed keywords

CISPLATIN; LEUPRORELIN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOVULATION; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; NONHUMAN; OVARIAN RESERVE; OVARY DISEASE; OVARY FOLLICLE; PRECAMBRIAN; PRESERVATION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; WISTAR RAT;

ANIMALS; ANOVULATION; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERTILITY; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; INFERTILITY, FEMALE; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; OVARIAN FOLLICLE; PACLITAXEL; RATS; RATS, WISTAR;

EID: 77949263073     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.054     Document Type: Article

References (34)

1. Sönmezer M., and Oktay K. Fertility preservation in female patients. Hum Reprod Update 10 (2004) 251-256
2. Oktay K., Sönmezer M., Öktem O., Fox K., Emons G., and Bang H. Absence of conclusive evidence for the safety and efficacy gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12 (2007) 1055-1066
3. Blumenfeld Z. Gender difference: fertility preservation in young women but not in man exposed to gonadotoxic chemotherapy. Minerva Endocrinol 32 (2007) 23-34
4. Mekhail T.M., and Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacoter 3 (2002) 755-766
5. Yucebilgin M.S., Terek M.C., Ozsaran A., Akercan F., Zekioglu O., Isik E., et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 44 (2004) 6-9
6. Gucer F., Balkanli-Kaplan P., Doganay, Yuce M.A., Demiralay E., Sayin N.C., et al. Effect of paclitaxel on primordial follicular reserve in mice. Fertil Steril 76 (2001) 628-629
7. Matsuo G., Ushijima K., Shinagawa A., Takahashi S.I., Fujiyoshi N., Takemoto S., et al. GnRH agonists acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Krume Med J 54 (2007) 25-29
8. Letterie G.S. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Human Reprod 4 (2004) 831-837
9. Smith B.J., Plowchalk D.R., Sipes I.G., and Mattison D.R. Comparison of random and serial sections in assessment of ovarian toxicity. Reprod Toxicol 5 (1991) 379-383
10. Shapiro C.L., and Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 344 (2001) 1997-2008
11. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., and Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 (1999) 2365-2370
12. Trimbos J.B., and Trimmers P. Chemotherapy for early ovarian cancer. Curr Opin Obstet Gynecol 16 (2004) 43-48
13. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics. CA Cancer J Clin 53 (2003) 5-26
14. De Laurentiis M., Cancello G., D'Agostino D., Giuliano M., Giordano A., Montagna E., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26 (2008) 44-53
15. Wang T.H., Wang H.S., and Soong Y.K. Paclitaxel-induced cell death. Where the cell cycle and apoptosis come together. Cancer 1988 (2000) 2619-2628
16. Mailhes J.B., Carabatsos M.J., Young D., London S.N., Bell M., and Albertini D.F. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res 423 (1999) 79-90
17. Kalil N.G., and McGuire W.P. Chemotherapy for advanced epithelial ovarian carcinoma. Best Pract Res Clin Obstet Gynaecol 16 (2002) 553-557
18. Ataya K., McKanna J.A., Wintraub A.M., Clark M.R., and LeMaire W. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45 (1985) 3651-3656
19. Yuan G.W., Shen K., and Yang J.X. Study of the prevention of chemotherapy-induced ovarian damage by gonadotropin-releasing hormone agonist in rat model. Zhonghua Fu Chan Ke Za Zhi 40 (2005) 666-669
20. Franke H.R., Smit W.M., and Vermes T. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol 20 (2005) 274-278
21. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 187 (2002) 93-105
22. Recchia F., Sica G., De Filippis S., Saggio G., Rosselli M., and Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 13 (2002) 417-424
23. Blumenfeld Z. How to preserve fertilityin young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 12 (2007) 1044-1054
24. Imai A., Furui T., Sugiyama M., and Tamaya T. Gonadotropin releasing hormone (GnRH) analogues in anticancer management: clinical applications and antiproliferative signaling. Curr Top Pharmacol 6 (2002) 119-128
25. Vickery B.H., and Nestor J.J. Luteinizing hormone-releasing hormone analogs. Development and mechanism of action. Sem Reprod Endocrinol 5 (1987) 353-355
26. Kang S.K., Tai C.J., Nathwani P.S., and Leung P.C. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulose-luteal cells. Endocrinology 142 (2001) 182-192
27. Imai A., Sugiyama M., Furui T., Tamaya T., and Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulose cell damage. Gynecol Obstet Invest 63 (2007) 102-106
28. Choi J.H., Gilks C.B., Auersperg N., and Leung P.C.K. Immunolocalization of gonadotrophin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 91 (2006) 4562-4570
29. Knight P.G., and Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 132 (2006) 191-206
30. Lacham- Kaplan O. In vivo and in vitro differentiation of male germ cells in the mouse. Reproduction 128 (2004) 147-152
31. Moe-Behrens G.H., Klinger F.G., Eskild W., Grotmol T., Haugen T.B., and De Felici M. Akt/PTEN signaling mediates estrogen-dependent proliferation of primordial germ cells in vitro. Mol Endocrinol 17 (2003) 2630-2638
32. Alletti G.D., Long H.J., Podratz K.C., and Cliby W.A. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. Gynecol Oncol 104 (2007) 212-216
33. Huang Y., Zhao X., Zhang Q., and Xin X. The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis. Gynecol Oncol 112 (2009) 409-414
34. Danforth D.R., Arbogast L.K., and Friedman C.I. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 83 (2005) 1333-1338